Evidence map›Paper›PMID 31870276›Full record

ArticleBMC bioinformatics2019

DDI-PULearn: a positive-unlabeled learning method for large-scale prediction of drug-drug interactions.

Yi Zheng, Hui Peng, Xiaocai Zhang, Zhixun Zhao, Xiaoying Gao, Jinyan Li

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Yi ZhengAdvanced Analytics Institute, Faculty of Engineering and Information Technology, University of Technology Sydney, 15 Broadway Ultimo, Sydney, 2007, Australia.
Hui PengAdvanced Analytics Institute, Faculty of Engineering and Information Technology, University of Technology Sydney, 15 Broadway Ultimo, Sydney, 2007, Australia.
Xiaocai ZhangAdvanced Analytics Institute, Faculty of Engineering and Information Technology, University of Technology Sydney, 15 Broadway Ultimo, Sydney, 2007, Australia.
Zhixun ZhaoAdvanced Analytics Institute, Faculty of Engineering and Information Technology, University of Technology Sydney, 15 Broadway Ultimo, Sydney, 2007, Australia.
Xiaoying GaoSchool of Engineering and Computer Science, Victoria University of Wellington, Cotton Building, Kelburn Campus, Wellington, 6140, New Zealand.
Jinyan LiAdvanced Analytics Institute, Faculty of Engineering and Information Technology, University of Technology Sydney, 15 Broadway Ultimo, Sydney, 2007, Australia. Jinyan.Li@uts.edu.au.ORCID http://orcid.org/0000-0003-1833-7413
University of Technology Sydney · AUVictoria University of Wellington · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-drug interactions (DDIs) are a major concern in patients' medication. It's unfeasible to identify all potential DDIs using experimental methods which are time-consuming and expensive. Computational methods provide an effective strategy, however, facing challenges due to the lack of experimentally verified negative samples.

resultsTo address this problem, we propose a novel positive-unlabeled learning method named DDI-PULearn for large-scale drug-drug-interaction predictions. DDI-PULearn first generates seeds of reliable negatives via OCSVM (one-class support vector machine) under a high-recall constraint and via the cosine-similarity based KNN (k-nearest neighbors) as well. Then trained with all the labeled positives (i.e., the validated DDIs) and the generated seed negatives, DDI-PULearn employs an iterative SVM to identify a set of entire reliable negatives from the unlabeled samples (i.e., the unobserved DDIs). Following that, DDI-PULearn represents all the labeled positives and the identified negatives as vectors of abundant drug properties by a similarity-based method. Finally, DDI-PULearn transforms these vectors into a lower-dimensional space via PCA (principal component analysis) and utilizes the compressed vectors as input for binary classifications. The performance of DDI-PULearn is evaluated on simulative prediction for 149,878 possible interactions between 548 drugs, comparing with two baseline methods and five state-of-the-art methods. Related experiment results show that the proposed method for the representation of DDIs characterizes them accurately. DDI-PULearn achieves superior performance owing to the identified reliable negatives, outperforming all other methods significantly. In addition, the predicted novel DDIs suggest that DDI-PULearn is capable to identify novel DDIs.

conclusionsThe results demonstrate that positive-unlabeled learning paves a new way to tackle the problem caused by the lack of experimentally verified negatives in the computational prediction of DDIs.

Indexed as

Drug InteractionsCluster AnalysisHumansSupport Vector MachineDrug interaction predictionPositive-unlabeled learningReliable negative samples

Identifiers

PMID31870276
PMCPMC6929327
OpenAlexW2997159096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.